At Goodwin, Ms. Grammel has been an active member of teams litigating three federal jury trials, one federal bench trial, and one federal preliminary injunction hearing. She has also worked on appellate matters in the Federal Circuit, the First Circuit, and the Supreme Judicial Court of Massachusetts, as well as inter partes review proceedings.
Representative matters include:
- Genentech, Inc. et al. v. Celltrion, Inc. et al., C.A. Nos. 18-95-CFC, 18-1025-CFC (D. Del.). Representing Celltrion and Teva in BPCIA dispute regarding proposed biosimilar to HERCEPTIN® involving 40 patents, including during the pre-suit patent dance and during ensuing litigation.
- Manufacturing Resources Int’l, Inc. v. Civiq Smartscapes, LLC et al., C.A. No. 17-269-RGA (D. Del.). Representing defendants against claims of patent infringement relating to digital outdoor displays.
- Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., C.A. Nos. 17-7111-KM, 18-1775-KM, 18-5288-KM (D.N.J.). Representing Dr. Reddy’s in second-wave infringement suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, including during preliminary injunction proceedings and expedited appeal therefrom.
- Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., No. 14-1451-RGA (D. Del.). Represented Dr. Reddy’s in Hatch-Waxman suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, resulting in trial judgment of non-infringement of all asserted claims. Directed a witness at trial and had substantial involvement in development and presentation of noninfringement defenses before and at trial. Asserted patents included formulation and process claims.
- Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., C.A. No. 14-1309-GMS (D. Del.). Represented Actavis in Hatch-Waxman suit regarding Actavis’s proposed generic version of QUILLIVANT® (methylphenidate), resulting in trial judgment of invalidity of all asserted claims. Asserted patents included pharmacokinetic and formulation claims.
- Veracode, Inc. et al v. Appthority, Inc., No. 12-10487-DPW (D. Mass.). Represented patent owner in infringement suit against a competitor asserting patents relating to analysis and review of source code, resulting in jury verdict and post-trial judgment as a matter of law of willful infringement and entry of a permanent injunction.
In addition to her IP work, Ms. Grammel was also one of the Goodwin attorneys on the federal trial team that defended former SAC Capital Advisors portfolio manager Mathew Martoma. In the largest-ever insider trading prosecution brought to trial, Mr. Martoma faced charges that he improperly obtained non-public information about the results of a high-profile pharmaceutical clinical trial and used this information to make trades resulting in profit and avoided losses of over $275 million.
Pro Bono
Ms. Grammel devotes a significant portion of her practice to pro bono projects. While at Goodwin, she has represented indigent clients in various matters including an appeal of eviction proceedings, pursuit of civil rights claims under 42 U.S.C. § 1983, and defense of criminal securities fraud allegations. Ms. Grammel has also assisted legal permanent residents in applying for U.S. citizenship and is currently representing four young girls in their petition for Special Immigrant Juvenile status.
In addition to these projects, in 2017, Ms. Grammel completed a six-month rotation with the Middlesex County District Attorney’s Office. During this time, she first-chaired fifteen trials, including five jury trials. Ms. Grammel also argued dozens of evidentiary and non-evidentiary motions, including successfully arguing for the admissibility of presumptively excluded evidence at a consolidated hearing addressing a group of cases brought in Woburn District Court prior to 2014.
Ms. Grammel is a member of the Boston Bar Association, the American Bar Association and the National Association of Women Lawyers.
